Immuron Limited
Market Cap
$4.83M
P/E Ratio
-1.42
EPS
$-0.53
Dividend Yield
0.00%
52-Week Range
$0.68 — $2.39
Volume
25.59K
Avg Volume
45.59K
Beta
0.43
P/E (TTM)
-1.42
Forward P/E
—
PEG Ratio
-0.11
P/S (TTM)
1.07
P/B (TTM)
0.65
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.44%
ROA (TTM)
-0.31%
ROIC
—
Gross Margin
0.64%
Operating Margin
-0.68%
Net Margin
—
Debt/Equity
0.00
Current Ratio
8.04
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.30%
EPS Growth (5Y)
-0.30%
Sales Growth (3Y)
+1.19%
Sales Growth (5Y)
+1.37%
EPS Est (This Year)
$-0.02
EPS Est (Next Year)
$-0.02
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.04
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
5.69M
Float
5.61M
Free Float %
98.47%
Sector
Healthcare
Industry
Biotechnology
Country
AU
Exchange
NASDAQ
IPO Date
2017-06-09
Employees
7
CEO
Steven George Lydeamore
Index Membership
—
Website
https://www.immuron.com.au
Immuron Limited (IMRN) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $4.83M, a P/E ratio of -1.42, IMRN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare IMRN against other stocks using dozens of fundamental and technical filters.
Immuron Limited (IMRN) has a trailing twelve-month (TTM) P/E ratio of -1.42. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Immuron Limited (IMRN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Immuron Limited (IMRN) has a market capitalization of $4.83 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.